KSI-301: antibody biopolymer conjugate in retinal disorders.

IF 2.3 Q2 OPHTHALMOLOGY Therapeutic Advances in Ophthalmology Pub Date : 2021-07-12 eCollection Date: 2021-01-01 DOI:10.1177/25158414211027708

Priya R Chandrasekaran, V G Madanagopalan

{"title":"KSI-301: antibody biopolymer conjugate in retinal disorders.","authors":"Priya R Chandrasekaran, V G Madanagopalan","doi":"10.1177/25158414211027708","DOIUrl":null,"url":null,"abstract":"<p><p>KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"13 ","pages":"25158414211027708"},"PeriodicalIF":2.3000,"publicationDate":"2021-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/25158414211027708","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414211027708","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 28

Abstract

KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

KSI-301:视网膜疾病的抗体生物聚合物偶联物。

KSI-301是一种新的玻璃体内抗血管内皮生长因子(VEGF)抗体生物聚合物偶联物，正在研究用于治疗年龄相关性黄斑变性(AMD)、糖尿病性黄斑水肿(DME)和视网膜静脉闭塞(RVO)。到目前为止，临床前和早期临床试验在视网膜血管疾病方面显示出有希望的结果。在使用抗vegf药物治疗视网膜疾病时，注射次数和随访次数增加了治疗负担，极大地影响了治疗效果。有新的抗vegf药物在地平线上，延长作用时间，耐久性，安全性和有效性，似乎解决了上述问题。PubMed检索和Medline检索更新的抗vegf药物，KSI-301，视网膜抗体生物聚合物偶联物，KODIAK KSI-301, DAZZLE研究，GLEAM研究，GLIMMER研究，GLOW研究和BEACON研究。这篇综述文章展示了与KSI-301相关的生物物理特性和正在进行的试验。此外，我们在现有试验结果的基础上讨论了KSI-301的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊